HR
SYRS

Howe & Rusling’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Howe & Rusling’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5
Closed -$1K – 912
2018
Q3 		$1K Sell
5
-10
-67% -$1.16K ﹤0.01% 827
2018
Q2 		$2K Hold
15
– – ﹤0.01% 704
2018
Q1 		$2K Buy
15
+5
+50% +$547 ﹤0.01% 812
2017
Q4 		$1K Buy
+10
New +$1.34K ﹤0.01% 808

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Howe & Rusling's SYRS Position: Q4 2018 in Review

Howe & Rusling sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2018, closing a stake of 5 shares — an estimated $1K sold.

Howe & Rusling first reported a position in SYRS in Q4 2017 and held it in 4 quarters. The position peaked at $2K in Q2 2018. 68 funds tracked by Wall St. Rank hold SYRS as of Q4 2018.

  • Howe & Rusling reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Howe & Rusling sold 5 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $1K.
  • Howe & Rusling first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Howe & Rusling's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2K in Q2 2018.
  • 68 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Howe & Rusling's 13F filing for Q4 2018, filed 4 Feb 2019.